Sequential use of methotrexate, folinic acid, and cytosine arabinoside in the treatment of acute leukemia.
D000328:Adult; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage* / Q000627:therapeutic use; D004247:DNA / Q000096:biosynthesis; D003857:Deoxyuridine / Q000494:pharmacology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D002955:Leucovorin / Q000008:administration & dosage* / Q000627:therapeutic use; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D008938:Mitosis / Q000187:drug effects; D013936:Thymidine / Q000378:metabolism; D013941:Thymine / Q000096:biosynthesis
D003561:Cytarabine; D004247:DNA; D002955:Leucovorin; D013941:Thymine; D013936:Thymidine; D003857:Deoxyuridine; D008727:Methotrexate